Cargando…
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
A fusion between the EML4 (echinoderm microtubule-associated protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit of patients. However, we have a poor understa...
Autores principales: | Bayliss, Richard, Choi, Jene, Fennell, Dean A., Fry, Andrew M., Richards, Mark W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761370/ https://www.ncbi.nlm.nih.gov/pubmed/26755435 http://dx.doi.org/10.1007/s00018-015-2117-6 |
Ejemplares similares
-
Phase‐separated foci of EML4‐ALK facilitate signalling and depend upon an active kinase conformation
por: Sampson, Josephina, et al.
Publicado: (2021) -
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022) -
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022) -
EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
por: Lucken, Kellie, et al.
Publicado: (2022) -
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
por: Sabir, Sarah R., et al.
Publicado: (2017)